 |
ARTPred
Joep de Mönnink, CEO and Co-Founder
Netherlands | Funding: €250K (+)
Website: http://artpred.com
ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
Website: http://artpred.com
ARTPred is developing technology intended to predict the odds of failure of an embryo to implant in the uterus during in-vitro fertilization procedures. The platform is based on biomarker profiles of the urogenital microbiome.
